Paper40834985
Combination nitazoxanide and auranofin treatment has synergistic anticancer activity in anaplastic thyroid cancer through enhanced activation of oxidative stress that leads to apoptosis.
Ghosh C and 12 others. Cancer Lett, 2025. Cited by 5 papers, by iCite.
Cite this record
ConductScience Library. Combination nitazoxanide and auranofin treatment has synergistic anticancer activity in anaplastic thyroid cancer through enhanced activation of oxidative stress that leads to apoptosis. Papers, record 40834985. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40834985
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Combination nitazoxanide and auranofin treatment has synergistic anticancer activity in anaplastic thyroid cancer through enhanced activation of oxidative stress that leads to apoptosis.
- PubMed
Topics19
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Apoptosis | Major topic |
| Thiazoles | Major topic |
| Auranofin | Major topic |
| Oxidative Stress | Major topic |
| Thyroid Carcinoma, Anaplastic | Major topic |
| Antineoplastic Combined Chemotherapy Protocols | Major topic |
| Thyroid Neoplasms | Major topic |
| Humans | |
| Nitro Compounds | |
| Drug Synergism | |
| Animals | |
| Cell Line, Tumor | |
| Cell Proliferation | |
| Xenograft Model Antitumor Assays | |
| Reactive Oxygen Species | |
| Mice, Nude | |
| Mice | |
| Cell Movement | |
| Female |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| ZIA BC011286 | Intramural NIH HHS | United States | ZIABC011286 | PubMed |
Source NIH RePORTER
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Erratum in | 41314952 | Corrigendum to "Combination nitazoxanide and auranofin treatment has synergistic anticancer activity in anaplastic thyroid cancer through enhanced activation of oxidative stress that leads to apoptosis" [Cancer Letters 633 (2025) 217990]. | https://conductscience.org/library/papers/41314952 |
Source PubMed
References54
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 39329036 | Estimation of Serum Malondialdehyde (a Marker of Oxidative Stress) as a Predictive Biomarker for the Severity of Coronary Artery Disease (CAD) and Cardiovascular Outcomes. | Cureus | 2024 | https://conductscience.org/library/papers/39329036 | PubMed |
| 2 | 23254900 | The intersecting roles of endoplasmic reticulum stress, ubiquitin- proteasome system, and autophagy in the pathogenesis of proteinuric kidney disease. | Kidney Int | 2013 | https://conductscience.org/library/papers/23254900 | PubMed |
| 3 | 38636790 | Therapeutic targeting of thioredoxin reductase 1 causes ferroptosis while potentiating anti-PD-1 efficacy in head and neck cancer. | Chem Biol Interact | 2024 | https://conductscience.org/library/papers/38636790 | PubMed |
| 4 | 36852389 | Drug Repurposing: An Effective Tool in Modern Drug Discovery. | Russ J Bioorg Chem | 2023 | https://conductscience.org/library/papers/36852389 | PubMed |
| 5 | 27821451 | Phase I Clinical Trial Results of Auranofin, a Novel Antiparasitic Agent. | Antimicrob Agents Chemother | 2017 | https://conductscience.org/library/papers/27821451 | PubMed |
| 6 | 32284020 | Dissecting Anaplastic Thyroid Carcinoma: A Comprehensive Clinical, Histologic, Immunophenotypic, and Molecular Study of 360 Cases. | Thyroid | 2020 | https://conductscience.org/library/papers/32284020 | PubMed |
| 7 | 29072975 | Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer. | J Clin Oncol | 2018 | https://conductscience.org/library/papers/29072975 | PubMed |
| 8 | 29501728 | Targeting of cathepsin C induces autophagic dysregulation that directs ER stress mediated cellular cytotoxicity in colorectal cancer cells. | Cell Signal | 2018 | https://conductscience.org/library/papers/29501728 | PubMed |
| 9 | 34638857 | ROS/TNF-α Crosstalk Triggers the Expression of IL-8 and MCP-1 in Human Monocytic THP-1 Cells via the NF-κB and ERK1/2 Mediated Signaling. | Int J Mol Sci | 2021 | https://conductscience.org/library/papers/34638857 | PubMed |
| 10 | 31937621 | A Combinatorial Strategy for Targeting BRAF V600E-Mutant Cancers with BRAFV600E Inhibitor (PLX4720) and Tyrosine Kinase Inhibitor (Ponatinib). | Clin Cancer Res | 2020 | https://conductscience.org/library/papers/31937621 | PubMed |
| 11 | 36775962 | Hypoxia-induced oxidative stress promotes therapy resistance via upregulation of heme oxygenase-1 in multiple myeloma. | Cancer Med | 2023 | https://conductscience.org/library/papers/36775962 | PubMed |
| 12 | 35624835 | Auranofin and Pharmacologic Ascorbate as Radiomodulators in the Treatment of Pancreatic Cancer. | Antioxidants (Basel) | 2022 | https://conductscience.org/library/papers/35624835 | PubMed |
| 13 | 37778414 | Synergistic lethality between auranofin-induced oxidative DNA damage and ATR inhibition in cancer cells. | Life Sci | 2023 | https://conductscience.org/library/papers/37778414 | PubMed |
| 14 | 39084502 | Anti-cancer effects of nitazoxanide in epithelial ovarian cancer in-vitro and in-vivo. | Chem Biol Interact | 2024 | https://conductscience.org/library/papers/39084502 | PubMed |
| 15 | 36014444 | Anti-Cancer Effects of Auranofin in Human Lung Cancer Cells by Increasing Intracellular ROS Levels and Depleting GSH Levels. | Molecules | 2022 | https://conductscience.org/library/papers/36014444 | PubMed |
| 16 | 37121274 | High-throughput approaches to uncover synergistic drug combinations in leukemia. | SLAS Discov | 2023 | https://conductscience.org/library/papers/37121274 | PubMed |
| 17 | 14640029 | Heme-oxygenase-1 response, a marker of oxidative stress, in a mouse model of AA amyloidosis. | Amyloid | 2003 | https://conductscience.org/library/papers/14640029 | PubMed |
| 18 | 35201489 | The gold complex auranofin: new perspectives for cancer therapy. | Discov Oncol | 2021 | https://conductscience.org/library/papers/35201489 | PubMed |
| 19 | 25560241 | Combined inhibition of glycolysis, the pentose cycle, and thioredoxin metabolism selectively increases cytotoxicity and oxidative stress in human breast and prostate cancer. | Redox Biol | 2015 | https://conductscience.org/library/papers/25560241 | PubMed |
| 20 | 33812801 | Auranofin reveals therapeutic anticancer potential by triggering distinct molecular cell death mechanisms and innate immunity in mutant p53 non-small cell lung cancer. | Redox Biol | 2021 | https://conductscience.org/library/papers/33812801 | PubMed |
Cited by2
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 5 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42035477 | CRISPR-Based Gene Dependency Screens Reveal Mechanism of BRAF Inhibitor Resistance in Anaplastic Thyroid Cancer. | Mol Carcinog | 2026 | https://conductscience.org/library/papers/42035477 | PubMed |
| 41963956 | Mitophagy in bladder cancer: a double-edged sword in tumor progression and therapy. | J Transl Med | 2026 | https://conductscience.org/library/papers/41963956 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| HMOX1 | 3162 | PubTator's text mining | https://conductscience.org/library/genes/3162 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40834985
GET https://conductscience.org/api/papers/v1/40834985/references?page=2